Adenine arabinoside in the management of herpetic keratitis. 1975

J I McGill, and D Coster, and T Frauenfelder, and A D Holt-Wilson, and H Williams, and B R Jones

Ara-A is an effective antiviral agent in the treatment of herpetic ulceration. Its use leads to a quick and high cure rate, and clinical resistance is low. It can successfully be used in cases showing complications after treatment with other antiviral agents.

UI MeSH Term Description Entries
D007065 Idoxuridine An analog of DEOXYURIDINE that inhibits viral DNA synthesis. The drug is used as an antiviral agent. 5-Iodo-2'-deoxyuridine,IUdR,Iododeoxyuridine,5-Iododeoxyuridine,Allergan 211,Herplex Liquifilm,Idoxuridine, 123I-Labeled,Idoxuridine, 125I-Labeled,Idoxuridine, 131I-Labeled,Idoxuridine, 3H-Labeled,Idoxuridine, Radical Ion (+1),Idoxuridine, Radical Ion (1-),Kerecide,NSC-39661,Oftan-IDU,SK&F-14287,Stoxil,123I-Labeled Idoxuridine,125I-Labeled Idoxuridine,131I-Labeled Idoxuridine,3H-Labeled Idoxuridine,5 Iodo 2' deoxyuridine,5 Iododeoxyuridine,Idoxuridine, 123I Labeled,Idoxuridine, 125I Labeled,Idoxuridine, 131I Labeled,Idoxuridine, 3H Labeled,Liquifilm, Herplex,NSC 39661,NSC39661,Oftan IDU,OftanIDU
D007635 Keratitis, Dendritic A form of herpetic keratitis characterized by the formation of small vesicles which break down and coalesce to form recurring dendritic ulcers, characteristically irregular, linear, branching, and ending in knoblike extremities. (Dictionary of Visual Science, 3d ed) Furrow Keratitis,Keratitis, Furrow,Dendritic Keratitides,Dendritic Keratitis,Furrow Keratitides,Keratitides, Dendritic,Keratitides, Furrow
D011684 Purine Nucleosides Purines with a RIBOSE attached that can be phosphorylated to PURINE NUCLEOTIDES. Purine Nucleoside,Nucleoside, Purine,Nucleosides, Purine
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004342 Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally. Allergy, Drug,Hypersensitivity, Drug,Drug Allergy,Allergies, Drug,Drug Allergies,Drug Hypersensitivities,Hypersensitivities, Drug
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014271 Trifluridine An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557) Trifluorothymidine,2'-deoxy-5-(trifluoromethyl)uridine,5-Trifluoromethyl-2'-deoxyuridine,TFT Ophtiole,Triflumann,Trifluoridine,Viromidin,Virophta,Viroptic,5 Trifluoromethyl 2' deoxyuridine
D014740 Vidarabine A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus. Adenine Arabinoside,Ara-A,Arabinofuranosyladenine,Arabinosyladenine,9-beta-Arabinofuranosyladenine,9-beta-D-Arabinofuranosyladenine,Ara A,Vira-A,alpha-Ara A,alpha-D-Arabinofuranosyladenine,beta-Ara A,9 beta Arabinofuranosyladenine,9 beta D Arabinofuranosyladenine,Arabinoside, Adenine,Vira A,ViraA,alpha Ara A,alpha D Arabinofuranosyladenine,beta Ara A

Related Publications

J I McGill, and D Coster, and T Frauenfelder, and A D Holt-Wilson, and H Williams, and B R Jones
April 1975, American journal of ophthalmology,
J I McGill, and D Coster, and T Frauenfelder, and A D Holt-Wilson, and H Williams, and B R Jones
January 1978, The Journal of international medical research,
J I McGill, and D Coster, and T Frauenfelder, and A D Holt-Wilson, and H Williams, and B R Jones
February 1978, Nippon Ganka Gakkai zasshi,
J I McGill, and D Coster, and T Frauenfelder, and A D Holt-Wilson, and H Williams, and B R Jones
December 1981, La Nouvelle presse medicale,
J I McGill, and D Coster, and T Frauenfelder, and A D Holt-Wilson, and H Williams, and B R Jones
May 1963, Archives of ophthalmology (Chicago, Ill. : 1960),
J I McGill, and D Coster, and T Frauenfelder, and A D Holt-Wilson, and H Williams, and B R Jones
January 1987, Current eye research,
J I McGill, and D Coster, and T Frauenfelder, and A D Holt-Wilson, and H Williams, and B R Jones
December 1964, Archives of ophthalmology (Chicago, Ill. : 1960),
J I McGill, and D Coster, and T Frauenfelder, and A D Holt-Wilson, and H Williams, and B R Jones
February 1979, La Nouvelle presse medicale,
J I McGill, and D Coster, and T Frauenfelder, and A D Holt-Wilson, and H Williams, and B R Jones
January 1982, Transactions of the Ophthalmological Society of New Zealand,
J I McGill, and D Coster, and T Frauenfelder, and A D Holt-Wilson, and H Williams, and B R Jones
January 1980, The British journal of ophthalmology,
Copied contents to your clipboard!